{"id":"endostar-routine-intravenous-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Hemorrhage"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Endostar is a truncated form of human endostatin, an endogenous angiogenesis inhibitor derived from collagen XVIII. It works by suppressing vascular endothelial growth factor (VEGF)-mediated endothelial cell proliferation and migration, thereby starving tumors of their blood supply. This anti-angiogenic mechanism reduces tumor growth and metastatic potential.","oneSentence":"Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:01.221Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Other solid tumors (in combination with chemotherapy)"}]},"trialDetails":[{"nctId":"NCT02283476","phase":"PHASE3","title":"The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2014-11","conditions":"Lung Cancer","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Endostar routine intravenous infusion","genericName":"Endostar routine intravenous infusion","companyName":"Jiangsu Simcere Pharmaceutical Co., Ltd.","companyId":"jiangsu-simcere-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors. Used for Non-small cell lung cancer (NSCLC), Other solid tumors (in combination with chemotherapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}